Haemoglobin and serum iron responses to periodic intravenous iron-dextran infusions during maintenance haemodialysis.
Patients with chronic renal failure who were on maintenance haemodialysis, were given monthly 600 mg iron intravenously as iron-dextran complex to a body replacement total of 5-6 g iron. Those patients who had been on maintenance haemodialysis for a long period and had received numerous blood transfusions failed to show a rise in haemoglobin levels. Those patients who received iron from the commencement of maintenance dialysis, and who had not received blood transfusions, showed a significant increase in haemoglobin concentrations which has been maintained for more than 18 months after iron therapy ceased, despite a concurrent decrease in serum iron concentrations. Pre-treatment and post-treatment levels of serum iron are not of predictive value for the success of iron treatment, neither for the haemoglobin nor the serum iron response. A body replacement dose of iron given intravenously over a year benefits the majority of patients on maintenance haemodialysis and is recommended for the treatment of their anaemia.
D000740:Anemia / Q000188:drug therapy; D001803:Blood Transfusion; D005260:Female; D005500:Follow-Up Studies; D006454:Hemoglobins; D006801:Humans; D007275:Injections, Intravenous; D007501:Iron / Q000097:blood*; D007505:Iron-Dextran Complex / Q000008:administration & dosage* / Q000627:therapeutic use; D008297:Male; D006435:Renal Dialysis
D006454:Hemoglobins; D007505:Iron-Dextran Complex; D007501:Iron